bioRxivCancer BiologyPreprint
In Luminal~A breast cancer, bulk FOXC1 reports the tumour vasculature, while a proliferation-independent basal-lineage axis marks the tumour cells
Abstract
Background: Candidate tumour-cell biomarkers identified from bulk transcriptomes are frequently expressed in stromal or vascular compartments as well, so a bulk correlation between such a gene and a biological programme can reflect tumour-cell biology or co-variation with those compartments. FOXC1, a PAM50 basal-defining transcription factor with canonical vascular expression, has immune associations in Luminal A breast cancer that have been read as tumour-cell-intrinsic. Methods: We developed a compartment-adjustment framework - purity- and stroma-adjusted partial correlations benchmarked across candidate marker genes - and applied it across three Luminal A cohorts (TCGA, (n=571); METABRIC, (n=700); SCAN-B, (n=1,540); two sequencing platforms) and single-cell data (GSE176078; 100,064 cells). Results: FOXC1's apparent adaptive-immune and tertiary-lymphoid-structure coupling is a vascular readout: it attenuates under adjustment for leukocyte-adhesion endothelial markers but persists under a structural-only endothelial composite, marking immune-recruiting vasculature. Single-cell analysis localises FOXC1 to the vessel wall-malignant cells contribute (1.8%) of FOXC1 transcripts versus (90%) from endothelial and perivascular cells. Basal cytokeratins (KRT5, KRT14, KRT17) and TP63, unlike FOXC1, retain a residual population-level basal-lineage signal; an apparent survival advantage is largely age-explained. Conclusions: Bulk FOXC1 in Luminal A originates principally from stromal--vascular compartments. Compartment adjustment offers a candidate approach for interpreting bulk biomarkers in heterogeneous tissue.
- organism: human
- assay: bulk RNA-seq
- assay: scRNA-seq
- research focus: cell type annotation
- research focus: differential expression
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- FOXA1 preserves cell polarity and restrains lysosome biogenesis in non-small cell lung adenocarcinoma
Xuecong Wang, B.G Zhang, … Jianxing He·bioRxiv·Apr 10, 2026
- Counterbalance of Foxp3 and IDO expression at different tumor stages in aggressive breast cancer subtypes
R. Canzoneri, E. Lacunza, … M. T. Isla Larrain·bioRxiv·Aug 23, 2021
- Pan-cancer analysis reveals the value of FDX1 as a novel biomarker in the prognosis and immunotherapy in human tumors
Qingqing Zhang, Nanyang Liu, … Ping Wang·bioRxiv·Jun 22, 2022
- Robust biomarker discovery through multiplatform multiplex image analysis of breast cancer clinical cohorts
- Transcriptomic Profiles from Normal and Tumor Tissue Samples Reveal Distinct Venule Populations and Novel Tumor Endothelial Cell Markers in Breast Cancer
Kathryn N. Phoenix, Vijender Singh, … Kevin P. Claffey·Breast Cancer ResearchPeer-reviewed·Mar 3, 2026
- FOXM1 Expression in Invasive Ductal Breast Carcinoma of No Special Type: Insights from RNA-seq and Immunohistochemical Analysis
Masahiro Ohara, Emi Mikami, … Toshiaki Saeki·bioRxiv·Sep 7, 2025